Related Experiment Video
Updated: May 13, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
New therapeutics in systemic lupus erythematosus
1Division of Rheumatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. zpaz@bidmc.harvard.edu
Current Opinion in Rheumatology
|March 16, 2013
Summary
New therapeutics for systemic lupus erythematosus (SLE) show promise, focusing on optimizing existing treatments like Belimumab and developing novel small molecule inhibitors. Research in mice aids understanding, though direct translation to human SLE remains challenging.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with ongoing therapeutic development.
- Current research focuses on refining existing treatments and exploring novel molecular targets.
Purpose of the Study:
- To review novel therapeutics for SLE, including approved and unapproved treatments.
- To discuss advancements published within the last year.
Main Methods:
- Review of recent clinical trials and preclinical studies.
- Analysis of small molecule inhibitors targeting proteasome and immune signaling pathways (Btk, ROCK, CaMK4).
- Evaluation of biologic agents, including Belimumab and Rituximab.
Main Results:
- Optimization of Belimumab and Rituximab use based on prior trial data.
- Development of new small molecule inhibitors targeting key signaling pathways.
- Recognition of limitations in preclinical models (lupus-prone mice) for predicting human SLE efficacy.
Conclusions:
- 2012 marked significant progress in SLE therapeutics, emphasizing targeted pathways.
- Small molecules and biological agents represent key areas of novel therapeutic development for SLE.
- Continued research is vital to bridge findings from preclinical models to effective human treatments.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...